These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 32697374)

  • 21. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.
    Furue K; Ito T; Furue M
    Cytokine; 2018 Nov; 111():182-188. PubMed ID: 30172115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of antiphospholipid autoantibodies associated with biologics treatment for psoriasis.
    Li L; Toyama S; Mizuno Y; Yamamoto T; Hiroshima A; Koyama A; Taira H; Sugimoto E; Ito Y; Awaji K; Tateishi S; Kanda H; Asano Y; Sato S; Shibata S
    Sci Rep; 2024 Jul; 14(1):15975. PubMed ID: 38987260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guselkumab for the Treatment of Psoriasis.
    Machado Á; Torres T
    BioDrugs; 2018 Apr; 32(2):119-128. PubMed ID: 29470778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secukinumab for treating plaque psoriasis.
    Rothstein B; Gottlieb A
    Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psoriasis and the TNF/IL23/IL17 axis.
    Furue K; Ito T; Tsuji G; Kadono T; Furue M
    G Ital Dermatol Venereol; 2019 Aug; 154(4):418-424. PubMed ID: 30648836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.
    No DJ; Amin M; Bhutani T; Wu JJ
    J Dermatolog Treat; 2018 Aug; 29(5):467-474. PubMed ID: 29103334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
    Alunno A; Carubbi F; Cafaro G; Pucci G; Battista F; Bartoloni E; Giacomelli R; Schillaci G; Gerli R
    Expert Opin Biol Ther; 2015; 15(12):1727-37. PubMed ID: 26653110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis.
    Kim J; Krueger JG
    Annu Rev Med; 2017 Jan; 68():255-269. PubMed ID: 27686018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Principles of biological therapy in psoriasis.
    Caca Biljanovska N; V'lckova Laskoska M
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2013; 34(1):143-53. PubMed ID: 23928807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis.
    Miyagawa H; Hara H; Araya J; Minagawa S; Numata T; Umezawa Y; Asahina A; Nakagawa H; Kuwano K
    PLoS One; 2021; 16(1):e0245284. PubMed ID: 33411857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequencing of Targeted Therapy in Psoriasis: Does it Matter?
    Boswell ND; Singla S; Gordon KB
    Am J Clin Dermatol; 2024 Sep; 25(5):795-810. PubMed ID: 39003351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases.
    Fragoulis GE; Siebert S; McInnes IB
    Annu Rev Med; 2016; 67():337-53. PubMed ID: 26565676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
    Tausend W; Downing C; Tyring S
    J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of emerging immunotherapies in psoriasis.
    Yiu ZZ; Warren RB
    Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologics for psoriasis: What is new?
    Özyurt K; Ertaş R; Atasoy M
    Dermatol Ther; 2019 May; 32(3):e12916. PubMed ID: 30972872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse Reactions to Biologics in Psoriasis.
    Lockwood SJ; Prens LM; Kimball AB
    Curr Probl Dermatol; 2018; 53():1-14. PubMed ID: 29131033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developments in systemic immunomodulatory therapy for psoriasis.
    Berger EM; Gottlieb AB
    Curr Opin Pharmacol; 2007 Aug; 7(4):434-44. PubMed ID: 17627886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.